SCHEMBL30049828

SCHEMBL30049828

CC(C)(C)CCN1CCC2(CC1)CCN(S(=O)(=O)c1ccc(N3CCOC3=O)nc1)C2

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.37
▸ KCNJ1 P48048 10/20 0.37
▸ KCNH2 Q12809 2/20 0.37
▸ GAA P10253 4/20 0.37
▸ KDM4E B2RXH2 2/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ LMNA P02545 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27161560 1.00 ALDH1A1 (0.37) ALDH1A1KCNJ1KCNH2GAAKDM4E
SCHEMBL27161927 0.96 TSHR (0.39) ALDH1A1KCNJ1KCNH2GAAKDM4E
SCHEMBL30051175 0.96 TSHR (0.39) ALDH1A1KCNJ1KCNH2GAAKDM4E
SCHEMBL30049349 0.95 ALDH1A1 (0.40) ALDH1A1KCNJ1KCNH2GAAKDM4E
SCHEMBL27161681 0.95 ALDH1A1 (0.40) ALDH1A1KCNJ1KCNH2GAAKDM4E
SCHEMBL30049755 0.91 CYP3A4 (0.41) ALDH1A1KCNJ1GAAKDM4ESMN1; SMN2
SCHEMBL27162570 0.91 CYP3A4 (0.41) ALDH1A1KCNJ1GAAKDM4ESMN1; SMN2
SCHEMBL30049333 0.85 ALDH1A1 (0.42) ALDH1A1KCNJ1KCNH2GAAKDM4E
SCHEMBL27161892 0.85 ALDH1A1 (0.42) ALDH1A1KCNJ1KCNH2GAAKDM4E
SCHEMBL30050950 0.85 GAA (0.39) ALDH1A1KCNJ1KCNH2GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US claimed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 ALDH1A1 1011/4885KCNJ1 1570/4885KCNH2 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback